The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 29, 2017

Filed:

Dec. 02, 2011
Applicants:

Stephan Fricke, Leipzig, DE;

Frank Emmrich, Leipzig, DE;

Nadja Hilger, Leipzig, DE;

Inventors:

Stephan Fricke, Leipzig, DE;

Frank Emmrich, Leipzig, DE;

Nadja Hilger, Leipzig, DE;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/0783 (2010.01); C12N 5/077 (2010.01); C12N 5/078 (2010.01); A61K 35/28 (2015.01); C07K 16/28 (2006.01); C12N 5/00 (2006.01); A61K 35/12 (2015.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0669 (2013.01); A61K 35/28 (2013.01); C07K 16/2812 (2013.01); C12N 5/0087 (2013.01); C12N 5/0648 (2013.01); A61K 2035/124 (2013.01); A61K 2039/505 (2013.01);
Abstract

The present invention relates to, among others, an in vitro method of modifying a cell graft containing immune cells comprising the steps of incubating a cell graft containing immune cells with an anti CD4 antibody wherein said incubating is carried out for from 1 minute to 7 days, b) removing unbound antibody from said graft; as well as to corresponding modified grafts and uses. The invention further relates to the modification of antibodies reactive to the CD4 human leukocyte antigen to provide anti-CD4 antibodies that have a reduced number of potential T-cell epitopes but retain the ability to bind to CD4, such as to an anti human CD4-antibody comprising a heavy chain immunoglobulin variable domain (VH) and a light chain immunoglobulin variable domain (VL), wherein at least one T cell epitope located outside the CDRs of said immunoglobulin variable domains is removed from said immunoglobulin variable domains. Preferably, the specificity and mode of action of the anti-CD4 antibodies are not affected by the modification(s).


Find Patent Forward Citations

Loading…